John A. Keller Ph.D. — - at Incyte Corporation

Dr. John A. Keller, Ph.D., has been the Chief Executive Officer and President at Shionogi Inc. since April 2011. Dr. Keller has been Executive Vice President of Corporate Development & Strategy at Shionogi USA, Inc. since July 2010. Dr. Keller is responsible for functions including corporate and business development, alliance management and strategic planning at Shionogi USA, Inc. He has been Senior Executive Officer of Shionogi & Co., Ltd. since April 2017 and served as its Corporate Officer. Dr. Keller served as a Partner of SR One. Dr. Keller served as an Executive Vice President of Corporate Development and Strategy at Shionogi, Inc. from July 2010 to April 2011. He served as the Chief Business Officer and Executive Vice President of Incyte Corporation from September 22, 2003 to September 12, 2008 and served as its General Manager of Information Products Group from December 16, 2003 to September 2008. Dr. Keller was with GlaxoSmithKline (GSK) since its formation in 2001 and with SmithKline Beecham since 1987. From January 2001 to September 2003 he served as Vice President of Business Development at GSK's Worldwide Business Development group and was directly involved in the establishment of numerous product licensing agreements with companies based in the United States, Europe and Japan. He worked with a wide range of collaborative partners including major global pharmaceutical businesses, mid-sized regional healthcare companies and emerging and late-stage biotechnology firms and was instrumental in developing varied and innovative deal structures including joint ventures and consortia. Dr. Keller served as Vice President and Director in the Alliance and Technology group of GSK and was responsible for technology in- and out-licensing, alliance management and strategy for SmithKline Beecham Research and Development. He played a pivotal role in establishing numerous technology alliances that contributed to GSK's leadership position in genomics, bioinformatics and high-throughput chemistry and screening. He served as the Chairman of Ezose Sciences Inc. from April 4, 2011 to December 2011. He serves as Director of ViiV Healthcare Limited. He has been a Director of Ezose Sciences Inc. since April 4, 2011 and Shionogi Inc. since April 2011. He served as a Director of Diadexus Inc. since January 6, 2004. Dr. Keller received BA degree in Biology from John Hopkins University and his PhD in Microbiology from Rutgers University.